Program
alpha 1-Antitrypsin
Also written as “Alpha-1 MP”, “GLASSIA” and “Alpha1-proteinase inhibitor”.
Its studies are mostly in alpha 1-Antitrypsin Deficiency · Pulmonary Disease, Chronic Obstructive · Pulmonary Emphysema · Graft vs Host Disease · Diabetes Mellitus, Type 1, led by 4 companies.
Drug pageAlpha 1-Antitrypsin: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Grifols | 131 open or running | phase 3since Feb 20, 2006 | Sep 12, 2005 | Sep 2028phase 3 · NCT02796937 |
| Takedaits history only | 70 open or running | phase 4since Nov 3, 2006 | Nov 3, 2006 | none ahead |
| CSLits history only | 31 open or running | phase 4since Dec 2, 2005 | Dec 2, 2005 | Sep 15, 2033phase 4 · NCT07326592 |
| Kamadaits history only | 30 open or running | phase 3since Dec 17, 2019 | Feb 24, 2011 | none ahead |
Also a collaborator on its studies: Baxalta Innovations GmbH, now part of Shire.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Grifols only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 12, 2005First study: phase 2 study in alpha 1-Antitrypsin DeficiencyFirst studyNCT00263887 · 77 enrolled · Denmark, Sweden, United Kingdom
- Feb 20, 2006Phase 3 study in alpha 1-Antitrypsin DeficiencyNCT00295061 · 24 enrolled · United States
- Mar 8, 2006Phase 3 study in alpha 1-Antitrypsin DeficiencyNCT00301366 · 38 enrolled · United States, United Kingdom
- Jun 13, 2007Phase 2 study in Cystic FibrosisNCT00486837 · 72 enrolled
- Sep 29, 2010Phase 2 study in EmphysemaNCT01213043 · 30 enrolled · United States
- Sep 6, 2012Phase 2 study in Cystic FibrosisNCT01684410 · 30 enrolled · United States
- Oct 28, 2013Phase 3 study in Pulmonary EmphysemaNCT01983241 · 345 enrolled · United States, Argentina, Australia and more
- Mar 11, 2014Phase 2 study in Diabetes Mellitus, Type 1NCT02093221 · 76 enrolled · United States
- Oct 31, 2014Phase 3 study in Alpha₁-Antitrypsin DeficiencyNCT02282527 · 32 enrolled · United States
- Jun 3, 2016Phase 3 study in Pulmonary EmphysemaNCT02796937 · 290 planned · United States, Australia, Canada and more
- Aug 12, 20162 phase 2 studies in alpha 1-Antitrypsin DeficiencyNCT02870348, NCT02870309
- Jul 28, 2020Phase 2 study in COVID-19NCT04495101 · 100 enrolled · Spain
Ahead
- Sep 2028Primary completion: phase 3 study in Pulmonary EmphysemaNCT02796937
TargetBeta
“Leukocyte elastase inhibitor”ChEMBL 37, by rule
Studies
All 13 Grifols leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04495101COVID-19 · Spain | 2 | Completed | Apr 26, 2021 | 100 |
| NCT02870348alpha 1-Antitrypsin Deficiency · Japan | 2 | Completed | Feb 16, 2021 | 4 |
| NCT02870309alpha 1-Antitrypsin Deficiency · Japan | 2 | Completed | Mar 15, 2017 | 4 |
| NCT02796937Pulmonary Emphysema · United States, Australia, Canada and more | 3 | By invitation | Sep 2028 | 290 |
| NCT02282527Alpha₁-Antitrypsin Deficiency · United States | 3 | Completed | Jan 2016 | 32 |
| NCT02093221Diabetes Mellitus, Type 1 · United States | 2 | Terminated | Jan 2017 | 76 |
| NCT01983241Pulmonary Emphysema · United States, Argentina, Australia and more | 3 | Completed | Jul 7, 2026 | 345 |
| NCT01684410Cystic Fibrosis · United States | 2 | Completed | Oct 2013 | 30 |
| NCT01213043Emphysema · United States | 2 | Completed | Jan 2012 | 30 |
| NCT00486837Cystic Fibrosis | 2 | Completed | Jun 2004 | 72 |
| NCT00301366alpha 1-Antitrypsin Deficiency · United States, United Kingdom | 3 | Completed | Mar 2007 | 38 |
| NCT00295061alpha 1-Antitrypsin Deficiency · United States | 3 | Completed | Feb 2007 | 24 |
| NCT00263887alpha 1-Antitrypsin Deficiency · Denmark, Sweden, United Kingdom | 2 | Completed | Jan 2007 | 77 |
How it is read
Names in the registry
- “Alpha-1 MP”, 5 entries
- “GLASSIA”, 2 entries
- “Alpha1-proteinase inhibitor”, 2 entries
- “Alpha1-Proteinase Inhibitor (Human)”, 2 entries
- “CE1226”, 1 entry
Conditions, from the studies’ own filings
- alpha 1-Antitrypsin Deficiency, 12 studies
- Pulmonary Disease, Chronic Obstructive, 3 studies
- Pulmonary Emphysema, 2 studies
- Graft vs Host Disease, 2 studies
- Diabetes Mellitus, Type 1, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.